Swathi Namburi, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen
    Topic:
    Advisory board, Daratumumab
    Date added:
    02/13/2023
    Date updated:
    05/09/2025
    Relationship end date:
    12/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Sanofi
    Topic:
    Ad board, Cablivi
    Date added:
    05/09/2025
    Date updated:
    05/09/2025
    Relationship end date:
    09/19/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    GSK
    Topic:
    Ad board, Blenrep
    Date added:
    05/09/2025
    Date updated:
    05/09/2025
    Relationship end date:
    05/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Targeted Oncology
    Topic:
    Bispecifics, speaker
    Date added:
    05/09/2025
    Date updated:
    05/09/2025
    Relationship end date:
    04/20/2025
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Ad board, Elrexfio
    Date added:
    05/09/2025
    Date updated:
    05/09/2025
    Relationship end date:
    05/25/2024
Return to 2025 Updates in Hematology and Oncology, Fresno